Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 1, 2022Cardiovascular DiabetologyOpen Access

Association of serum levels of osteopontin and osteoprotegerin with adverse outcomes after endovascular revascularisation in peripheral artery disease

View Full Paper
Ask AI
Bookmark
Share

Authors

NKNikolaos P. E. KadoglouHeart Failure & TransplantDKDimitrios KapetaniosAsklepios Klinik LangenEKEmmanouil KorakasPreventive Cardiology

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Kadoglou et al. (2022) studied this question.

synapsesocial.com/papers/6a1603ce366ced26f1b55ff8https://doi.org/10.1186/s12933-022-01605-6
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Plasma Osteopontin Levels and Adverse Cardiovascular Outcomes in the PEACE Trial2016 · 49 citations
  2. 2Association between carotid plaque vulnerability and high mobility group box-1 serum levels in a diabetic population2021 · 25 citations
  3. 3Association of plasma osteoprotegerin levels with the severity of lower extremity arterial disease in patients with type 2 diabetes2015 · 18 citations
  4. 4Association of Circulating Osteopontin Levels With Lower Extremity Arterial Disease in Subjects With Type 2 Diabetes Mellitus: A Cross-Sectional Observational Study2020 · 7 citations
  5. 5Prognostic significance of plasma osteopontin levels in patients with chronic stable angina2006 · 90 citations